A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison
with Botox for a total of 12 weeks after the administration in treatment of glabellar frown
lines.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ATGC Co., Ltd.
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A